10-Q · May 13, 2026
STAAR Surgical reported a robust Q1 2026 with net sales of $93.5 million, a significant 119.6% increase year-over-year, indicating a strong recovery. The company achieved net income of $5.2 million or $0.10 per diluted…
Earnings analysis · 10-Q
STAA earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
STAAR reported $93.5 million of revenue, ahead of the $90.6 million consensus estimate, with gross margin of 74.5% and operating margin of 10.8%. EPS improved to $0.16 but missed the $0.19 estimate, producing a mixed…
Read full summary
STAAR reported $93.5 million of revenue, ahead of the $90.6 million consensus estimate, with gross margin of 74.5% and operating margin of 10.8%. EPS improved to $0.16 but missed the $0.19 estimate, producing a mixed quarter despite strong China-driven growth. Management indicated strong year-over-year growth is expected in Q3 excluding the $25.9 million one-time Q3 2025 order and is planning for growth in Q4, but provided no formal numeric guidance.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.16
- Segment
- China revenue: $52.3 million, a primary driver of year-over-year growth
- Segment
- Other segment revenue: not disclosed in the provided filing extract
What stood out
-
Revenue beat estimates
Revenue was $93.5 million, up approximately 112.5% from $44.0 million in Q2 2025 but down approximately 0.5% from $94.0 million in Q1 2026; revenue exceeded the $90.6 million consensus estimate by approximately $2.9 million.
-
Margins improved
Gross margin was 74.5%, up 0.9 percentage points from 73.6% in Q1 2026 and 0.5 points from 74.0% in Q2 2025. Operating margin improved to 10.8% from 8.5% sequentially and negative 67.6% year over year.
-
EPS turned higher but missed
GAAP diluted EPS was $0.16, up from $0.10 in Q1 2026 and $(0.34) in Q2 2025, but below the $0.19 consensus estimate by $0.03.
-
China drove growth
China revenue was $52.3 million and was identified as the principal driver of the year-over-year revenue increase.
-
Near-term growth outlook remains positive
Management expects strong year-over-year Q3 growth even excluding the $25.9 million one-time order in Q3 2025, and is planning for year-over-year growth in Q4.
-
Controls remained effective
Disclosure controls were assessed as effective as of July 3, 2026, and there were no changes in internal control over financial reporting that materially affected or were reasonably likely to materially affect controls during the quarter.
What to watch
-
China concentration
China revenue was $52.3 million, representing a substantial concentration of quarterly sales and increasing exposure to China demand, regulatory, and geopolitical conditions.
-
Difficult comparison distortion
The company’s Q3 comparison excludes a $25.9 million one-time Q3 2025 order, making reported year-over-year growth sensitive to the treatment of that order and potentially masking underlying demand trends.
-
No updated risk-factor disclosure
The filing states that no material changes in market risk occurred during the six months ended July 3, 2026; however, the company remains exposed to the market and operating risks described in the January 2, 2026 Form 10-K.
-
Product and regulatory claims
The company is involved in legal proceedings, claims, regulatory actions, and product-liability or medical-device-quality matters in the ordinary course; although no known claim is expected to materially affect results, unexpected outcomes could cause significant financial harm.
Management's outlook
No formal numeric EPS or revenue guidance was provided. Management expects strong year-over-year growth in Q3 excluding the $25.9 million one-time Q3 2025 order and is planning for year-over-year growth in Q4.
Earlier filings 4
10-K · March 3, 2026
STAAR Surgical describes a focused, product-led strategy centered on its EVO family of Implantable Collamer Lenses (ICLs) and reports that for the fiscal year ended January 2, 2026 approximately 100% of net sales were…
10-Q · November 5, 2025
STAAR reported Q3 net sales of $94,732,000, up from $88,590,000 in the year-ago quarter, with gross margin expanding to 82.2% and operating income rising to $18,490,000. Diluted EPS was $0.18 (vs. $0.20 a year ago) and…
10-Q · August 6, 2025
STAAR reported Q2 net sales of $44,320,000 and GAAP diluted loss per share of $0.34, with an operating loss of $29,964,000 (74.0% gross margin). Results improved versus the prior quarter (revenue +$1.32M, EPS improved…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.